Sleep complaints are widespread and under diagnosed in HIV-seropositive ambulatory patients. This study sought to assess the severity and prevalence of sleep complaints in patients attending an adult outpatient HIV/AIDS clinic at an urban teaching hospital and to determine their correlation to the CD4 count and use of HAART medications.
The study design is a cross sectional survey. Fifty-two seropositive adults (29 men, 23 women), completed a 14 item self rated questionnaire on sleep complaints over the past month. In addition, records were reviewed for hemoglobin, CD4+ cell number, viral load, lactate dehydrogenase and combination antiretroviral therapy.
39 patients out of 52 (75%) reported 3 or more sleep complaints. CD4, viral load, and effect of HAART medication were tested to see if any of these variables had an effect on the results of the sleep disturbance questionnaire. An alpha level of 0.05 was used for all statistical procedures. The effect of viral load on the results of the sleep questionnaire was tested using an independent t test and found to be not significant (t48=0.242, p=0.813). The effect of use of HAART medication was also tested by independent t test and found to be not significant (t50=0.183, p=0.855). The relationship of CD4 (r50=−.137, p=0.334), hemoglobin (r50=−.117, p=0.408), and LDH (r30=−.016, p=0.931) with the results on the sleep questionnaire were tested and found to be not significant. Residual analysis was performed on the regression data to determine if there was any non linear component to the relationship and none was found.
This study confirms the high prevalence of sleep complaints in HIV infected population. This study fails to demonstrate any correlation between the severity of sleep complaints and worsening CD4+ counts or an increase in viral load in this population. Use of HAART medications did not significantly influence the prevalence of sleep complaints.
Further studies are needed to improve our fundamental understanding of sleep disturbances in HIV infected people.
Rohit Malik, No Financial Disclosure Information; No Product/Research Disclosure Information